The highest burden of breast cancer deaths is due to luminal tumors (70 to 80% of all newly diagnosed cases) that later recur as metastatic and therapy-resistant disease [~20% of the initial estrogen receptor-α–positive (ER+) cases] (1, 2). Here, ESR1 is linked to breast cancer.